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The automatic implantable cardioverter-defibrillator 
(AICD) effectively prevents death due to ventricular tachy- 
cardia or ventricular fibrillation. Some patients who need 
an AICD also require cardiac pacing to treat symptomatic 
hradycardia, hradycardia after defibrillation, or to provide 
a rate floor to reduce the frequency of hradycardia-related 
ventricular arrhythmias. Some patients also can benefit 
from antitachycardia pacing. A mapping technique to 
implant a pacemaker and AICD sensing leads is presented. 
For patients with a pacemaker who later need an AICD, the 
left ventricle is mapped with use of the AICD rate-sensing 
electrodes to identify a site at which the minimal pacemaker 
stimulus and maximal ventricular electrogram amplitudes 
are recorded. An external cardioverter-defibrillator that 
has amplifiers similar to those in the AICD is used to 
monitor the rate-sensing electrogram. For patients with an 
implanted AICD, pacemaker implantation is undertaken 
KIRKLIN. MD, FACC* 
by mapping the right ventricle with the pacemaker lead 
while the AICD is in standby mode; the AICD beep monitor 
is then used to determine a site where pacemaker stimulus 
detection by the AICD does not occur. 
Eight patients underwent implantation of a combined 
AICD-pacemaker system (four ventricular atititachycardia 
pacemakers, three ventricular demand pacemakers and 
one atrial demand pacemaker). Neither inhibition of AICD 
arrhythmia detection nor double counting occurred. Satis- 
factory AICD-pacemaker function was shown in all patients 
postoperatively, and no pacemaker malfunction was oh- 
served. Thus, with currently available technology, a com- 
bined AICD-pacemaker system can be implanted with 
satisfactory function of both devices and without adverse 
device-device interactions. 
(J Am Co11 Cardiol 1989;13:121-31) 
The automatic implantable cardioverter-defibrillator (AICD. 
Cardiac Pacemakers, Inc.) effectively prevents death due to 
ventricular tachycardia or ventricular fibrillation (l-3). Some 
patients who need an AICD also require cardiac pacing to 
treat underlying symptomatic bradycardia, severe bradycar- 
dia after defibrillation, or to provide a rate floor to reduce the 
frequency of bradycardia-related ventricular arrhythmias 
(4-8). 
Some patients also have hemodynamically well tolerated 
ventricular tachycardia and remain alert during their 
arrhythmia. The discomfort of electrical cardioversion there- 
fore makes the use of the AICD as the sole antiarrhythmic 
therapy for these individuals difficult. Although antitachy- 
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cardia pacemakers can terminate many episodes of these 
slower ventricular tachycardias @-IO), the possibility of rate 
acceleration has led to interest in combining the capabilities 
of antitachycardia pacing, cardioversion and defibrillation 
into a single device (6, I I, 12). 
The currently available AICD does not incorporate pace- 
maker capability. Although future implantable defibrillators 
will have pacing capabilities. at present when both an AICD 
and a pacemaker are needed, the leads and pulse generator 
for each device must be implanted separately. However, 
implantation of the devices in combination has been prob- 
lematic (13-16). Although interactions between the AlCD 
and pacemakers have been described (2,17-24), there are 
only isolated detailed reports of combined AICD and pace- 
maker implantation (7,25,26). This communication describes 
techniques for the implantation of a combined AICD- 
pacemaker system in patients with life-threatening ventricu- 
lar arrhythmias who require either pacing for bradycardia or 
antitachycardia pacing for ventricular tachycardia. 
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Table 1. Summary of Eight Patients With Combined AICD and Pacemaker Implantation 
Patient Patient Patient Patient Patient Patient Patient Patient 
I 2 3 4 5 6 7 8 
Age/gender 56/M 56/M 54/M 67/M 56/M 73/F 62/M 59/M 
Underlying disease CAD CAD CAD CAD CAD IDCM CAD CAD 
Clinical rhythms VT VT, VT, VT VTIVF, VF. VTIVF, VTIVF, SB. 
Afllslow SBilong AfliSSS Afibislow sss long QT 
VR HV VR 
EF 0.13 0.21 0.17 0.29 0.28 0.33 0.20 0.28 
AICD 
Model 1520 1520 1520 1520 1520 AID-B 1520 1520 
Rate (beatsimin) 202 204 204 162 203 174 176 203 
PDF Absent Absent Absent Absent Absent Present Absent Absent 
Energy (J)* 31131 32133 31131 31131 30130 26130 30130 30130 
Pacemaker model Telectronics Telectronics Intermedics Intermedics Medtronic Medtronic Medtronic Telectronics 
4171 4171 262-14 262-14 8412 8400 8420 5282A 
(PASAR) (PASAR) (Intertach) (Intertach) (Activitrax (Activitrax) (Spectrax) (Optima 
II) MPT) 
Implant order P-tAICD P+AICD P-tAICD P+AICD P+AICD AICWP P+AICD P+AICD 
No. of drugs failed 9 10 5 3 6 Nl 5 9 
*Energy delivered for first and subsequent shocks. Afib = atrial fibrillation; AA = atrial flutter; AICD = automatic implantable cardioverter-defibrillator: CAD 
= coronary artery disease; EF = ejection fraction; F = female; HV = HV interval: IDCM = idiopathic dilated cardiomyopathy; M = male; NI = noninducible; 
P = pacemaker; PDF = probability density function; QT = QT interval; SB = sinus bradycardia; SSS = sick sinus syndrome; VR = ventricular response; VF 
= ventricular fibrillation; VT = ventricular tachycardia. 
Methods 
Patients. Between September 12, 1984 and April 7, 1988 
at the University of Alabama at Birmingham, 65 automatic 
implantable cardioverter-defibrillators (AICD) were im- 
planted in 46 patients. Eight of these patients also required a 
pacemaker and constitute the study group (Table 1). Four 
patients had hemodynamically well tolerated ventricular 
tachycardia effectively terminated by antitachycardia pac- 
ing. The AICD was implanted as backup for treating possible 
tachycardia acceleration precipitated by pacing. One of 
these four patients also required ventricular demand pacing 
for high degree atrioventricular block (Patient 2) and another 
had sinus bradycardia with a long HV interval (Patient 3). 
The other four patients had both hemodynamically unstable 
ventricular tachyarrhythmias and important bradycardias 
requiring demand pacing. One of these patients had a de- 
mand pacemaker implanted because pacing had been shown 
to markedly decrease the frequency of episodes of polymor- 
phic ventricular tachycardia. 
Preoperative evaluatioh. Before AICD implantation, each 
patient was evaluated with electrocardiography, ambulatory 
monitoring, echocardiography, radionuclide ventriculogra- 
phy, coronary angiography, left ventriculography and elec- 
trophysiologic study. A treadmill exercise test was also 
performed whehever possible to determine the maximal 
ventricular rate during exercise and to assess if there was 
overlap in the rates of the supraventricular rhythms and 
ventricular tachycardia. Before implantation of an antitachy- 
cardia pacemaker, ~50 and preferably 100 successful con- 
versions of the stable ventricular tachycardia by pacing were 
required. Antitachycardia pacemaker implantation was per- 
formed with Institutional Review Board approval after the 
patienls had given fully informed consent. 
Devices. The AICD was used in all patiedts. One patient 
underwent implantation of an AID-B device; the other seven 
had a Ventak model 1520 device implanted. 
Six different pacemakers u’ere used. A Telectronics 
PASAR model 4171 antitachycardia pulse generator was 
implanted in two patients. This device automatically detects 
and responds to the presence of a tachycardia when ~5 
consecutive RR intervals occur at a rate faster than a 
preprogrammed tachycardia detection rate. Two patients 
underwent implantation of an Intermedics Intertach model 
262-14 pulse generator. For tachycardia recognition, this 
device has the capability of assessing rate, cycle length 
stability, change in cycle length at tachycardia onset and the 
number of tachycardia cycles at a particular cycle length. 
One patient each underwent implantation of Activitrax 
model 8400 and 8412 activity-sensing, rate-adaptive ventric- 
ular demand pulse generators (Medtronic, Inc.). The model 
8412 device is capable of programmable polarity. The sev- 
enth and eighth patients had a Medtronic model 8420 ven- 
tricular demand pulse generator and a Telectronics model 
5282A atrial demand pulse generator implanted, respec- 
tively. 
Potential device interactions investigated. Detection inhi- 
bition (1.3). Ventricular demand pacemakers may fail to 
sense ventricular tachycardia or ventricular fibrillation. 
Therefore, pacing stimuli may be delivered asynchronously 
during these arrhythmias. If compared with the R waves of 
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the tachycardia the pacemaker stimuli in the AICD rate- 
sensing electrogram are large, the AICD automatic gain 
control may filter the lower amplitude signals of the tachy- 
cardia and cause the AICD to interpret the pacemaker 
stimuli as a nontachycardia rhythm, thereby leading to 
failure of the AICD to detect the arrhythmia. Prior investi- 
gators have emphasized that this problem may be greater 
with unipolar ventricular pacemakers. Nevertheless, detec- 
tion inhibition may also occur when bipolar pacemaker 
stimuli are large (23). 
Double counting C13). If the interval between the pace- 
maker stimulus and the R wave in the bipolar AICD sensing 
electrogram is greater than the 150 to 160 ms refractory 
period of the AICD, both signals may be interpreted as 
ventricular depolarizations. If these signals occur together at 
a combined rate greater than the AICD tachycardia detec- 
tion rate, the AICD rate detection criterion will be satisfied. 
a charging cycle will be initiated and a shock will be 
delivered even though the underlying cardiac rhythm was 
neither ventricular tachycardia nor ventricular fibrillation. 
AICD diwhrrrgc precipitrrted by pacing rrho~~ the AICD 
tachycardicr detection rcrtr. Even in the absence of double 
counting, pacing at a rate and duration that satisfy the AICD 
rate-sensing criterion may initiate an AICD charging cycle 
and subsequent discharge although the underlying rhythm 
would not result in a discharge. 
AICD-induced prrcrmrrker malfirnction (13,17.18,22). 
Pacemakers may be reprogrammed or damaged by AICD 
discharges. In addition, if during or after an episode of 
ventricular tachycardia or ventricular fibrillation the pacing 
threshold increases, ineffective pacing may occur if the 
pacemaker stimulus becomes subthreshold. 
The AICD and the pacemaker were implanted at separate 
procedures in all patients. The pacemakers were implanted 
in the prepectoral region and the AICD in the anterior left 
upper quadrant of the abdomen to maximize the distance 
between the devices and thereby avoid magnet and program- 
mer interaction between the devices. 
Implantation of an AICD in patients with a previously 
implanted pacemaker. Four surface electrocardiographic 
(ECG) leads (I, II. III and aVR) and electrograms between 
the defibrillating leads and the bipolar epicardial sensing 
leads were recorded on an Electronics-for-Medicine VR-16 
switched beam oscilloscopic recorder. Two patch electrodes 
(model L67 or A67. Cardiac Pacemakers, Inc.) were always 
used because defibrillation thresholds are usually lower than 
those when a right atrial-superior vena cava spring electrode 
(model C IO, Cardiac Pacemakers) is used (23). The external 
cardioverter defibrillator (ECD, Intec Systems, Inc.) was 
used to monitor the cardiac electrograms from the AICD 
sensing and defibrillating leads. The patients were positioned 
to allow access with both a magnet and programmer head 
away from the sterile operative field. So as to mimic a 
“worst case scenario,” the pacemaker was programmed to 
its highest stimulus amplitude and duration to maximize the 
size of the pacemaker stimulus and increase the possibility of 
sensing by the AICD. The same techniques were used when 
implanting an AICD in the presence of either an atrial or a 
ventricular pacemaker. 
After the wrdiw electrogrrrm signuls rrwe calibrated, 
mrrpping of the left ventricle M~S performed to locate a site 
at which the pacemaker stimulus artifact size was as small as 
possible in the rate-sensing electrogram of the AICD. The 
bipolar epicardial sensing electrodes of the AICD (model 
KS4, Cardiac Pacemakers, Inc.) were left in their carriers 
and held by the surgeon with the electrode tips within 1 cm 
of each other (Fig. I). The electrodes were thereafter moved 
to various sites over the left ventricular epicardium during 
high output pacing to identify a site where the amplitude of 
the pacemaker stimulus was as small as possible both in 
absolute amplitude and relative to the native and paced R 
waves. The R wave amplitudes optimally exceeded 7 mV. A 
pacemaker stimulus and paced R wave “map” was thereby 
constructed (Fig. 2A). If a long stimulus to R wave interval 
was observed, the bipolar leads were moved closer to the 
pacemaker electrode. Mapping was performed before the 
patch leads were implanted to avoid placing the patches over 
the optimal bipolar sensing site. 
When (I site ~IYLS lourted r~&rr the prrwmrrkrr stimulus 
umplitudr MUS minimul and the R ~uvr rlmplitlrde MYIS lurgr 
in both I.entriculur prrced rend sirlus rhythm, one of the 
epicardial screw-in leads was implanted. The second epicar- 
dial screw-in electrode was then moved circumferentially 
within I cm around the implanted leads to identify the site 
where the smallest pacing stimulus was recorded. However, 
because the sensing vector may change as the screw-in 
electrode enters the myocardium, the amplitudes of the 
pacemaker stimulus artifact and R wave may also change. 
Thus, the amplitude of the pacemaker stimulus and R wave 
during pacing and sinus rhythm were always remeasured 
after the second screw-in electrode was implanted (Fig. 2B 
and 2C). When the patient was discharged from the hospital, 
the pacemaker was reprogrammed to a lower output as 
clinically indicated, resulting in pacemaker stimuli of smaller 
amplitude (Fig. 2B). 
After the bipolar leads 1i’ere implunted, the putch elec- 
trodes \~~e,e implrrrlted follo,~~ed by cwdio~wsion md defy- 
brillation threshold testing in the usrral fkshion (14-16,23). 
Special attention was paid to the behavior of the implanted 
pacemaker during both ventricular tachycardia (Fig. 3A) and 
ventricular fibrillation (Fig. 3B and 3C) to determine whether 
pacing occurred during these arrhythmias and whether the 
pacemaker stimulus artifact was visible in the electrogram 
recorded with use of the AICD bipolar sensing electrodes. 
When srltisfkctory currlio~~ersion and dejibrillation 
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Figure 1. Mapping the left ventricle for pacemaker 
stimulus artifact. The surgeon holds the bipolar epicar- 
dial electrodes in their lead carriers (center) attached to 
the monitoring cables (left). While held close together, 
the electrodes are carefully applied to the surface of the 
heart at multiple locations during pacing. Recordings 
made with the external cardioverter-defibrillator are 
analyzed on-line and a pacemaker stimulus artifact and 
paced R wave map is constructed. This photograph was 
made by the animal laboratory for illustrative purposes. 
thresholds were established, the AICD was implanted. To 
assess the actual sensing performance of the AICD, the 
magnet was left over the AICD after activation so that the 
AICD functioned in the standby (“EP”) mode. If during 
ventricular pacing double beeping was heard (one beep for 
the pacemaker artifact and one for the QRS response), then 
double counting was considered to be present. In addition, 
the pacemaker was also programmed to >50% of the AICD 
detection rate to observe whether an AICD charging cycle 
was initiated that suggested the occurrence of double count- 
ing. 
The performance of the AICD and the pacemaker were 
then tested during both ventricular tachycardia and ventric- 
ular fibrillation to observe whether the pacing occurred 
during ventricular tachycardia (Fig. 4A) or ventricular fibril- 
lation (Fig. 4B) and whether the AICD accurately detected 
these arrhythmias. For those individuals with an antitachy- 
cardia pacemaker, conversion of ventricular tachycardia 
was also tested in the operating room (Fig. 4C). 
Implantation of a pacemaker when an AICD is already 
implanted. For pacemaker implantation, the AICD was 
placed in the standby (“EP”) mode and the pacemaker lead 
was advanced to the right ventricle. A pacing system ana- 
lyzer (Medtronic model 531 I) programmed to maximal out- 
put and pulse width was used for pacing. The lead was then 
positioned to find a site that had acceptable pacing and 
sensing characteristics and avoided AICD sensing of the 
pacing stimulus, as detected by listening for double beeping 
from the AICD. Use of an active fixation lead facilitated 
positioning at a site satisfying these criteria. The lead and 
pacemaker were then implanted. 
Postoperative evaluation. In patients with a combined 
AICD and pacemaker system, a postoperative electro- 
physiologic study was performed before the patient was 
discharged from the hospital. At this study, the pacemaker 
was again programmed to its maximal stimulus amplitude 
and duration. For patients with ventricular tachycardia, this 
rhythm was always induced whether or not an antitachycar- 
dia pacemaker was implanted. For individuals with a com- 
bined antitachycardia pacemaker and AICD system, ventric- 
ular tachycardia was induced and terminated multiple times. 
Finally, regardless of whether a patient had experienced 
ventricular fibrillation clinically, this arrhythmia was always 
induced and tested. Special attention was paid to the follow- 
ing questions: What tachycardias and rates were observed? 
Did the AICD discharge reprogram or injure the pacemaker? 
Did the pacemaker cause AICD oversensing, double count- 
ing or detection inhibition? Did antitachycardia pacing ac- 
celerate the tachycardia? 
Results 
Postoperative electrophysiologic studies. Seven of the 
eight patients underwent postoperative electrophysiologic 
study. The eighth patient had multiple successful conver- 
sions of arrhythmia after implantation. Each patient tested 
had ventricular fibrillation induced that was successfully 
terminated in each case (Fig. 5 and 6). 
Patient 8 with an atria1 demand pacemaker had a defibril- 
lation threshold of 25 J in the operating room. At postoper- 
ative electrophysiologic study (Fig. 6), ventricular fibrilla- 
tion was induced by rapid ventricular pacing. These 
recordings demonstrated continued atria1 pacing during ven- 
tricular fibrillation. The AICD not only sensed the arrhyth- 
mia and delivered an appropriate discharge but also was able 
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Figure 2. A and B, Recordings from Patient 5 with a Medtronic 
Activitrax II activity-sensing, rate-adaptive pacemaker at automatic 
implantable cardioverter-defibrillator (AICD) implantation. Shown 
are surface ECG leads I. II, III, aVR and the electrogram recorded 
from the AICD bipolar epicardial leads (Bi). The gain for all 
recordings is identical. A, Epicardial recordings from one right 
ventricular (RV) and three left ventricular (LV) sites are shown 
during pacing at high stimulus amplitude (8 V) and duration (2 ms). 
The pacemaker stimulus artifact is extremely large close to the apex 
of the right ventricle and at left ventricular sites 1 and 2. Left ventricular 
site 3 is the location where the AICD bipolar sensing electrodes were 
implanted because the pacemaker stimulus artifact at this rate has a 
modest amplitude and is relatively small compared with that of the 
paced R wave. B, The AICD sensing leads are implanted. The R wave 
during sinus rhythm is 8.7 mV (left column). During bipolar pacing 
(middle columns) the pacemaker stimulus amplitude and pulse width 
are shown below the stimulus artifacts. As the programmed pace- 
maker stimulus amplitude is decreased, the stimulus artifact similarly 
decreases as recorded in the AICD bipolar sensing lead (Bi). During 
unipolar pacing (right column) when the pacing stimulus amplitude is 
only 2.5 V, the stimulus artifact amplitude is larger than that at any 
bipolar pacing output. C, Recordings from Patient 8 with a Telectro- 
nits (model 5282A) atria1 demand pacemaker demonstrate virtually 
no identifiable pacemaker stimulus artifacts (asterisks) in the AICD 
bipolar sensing electrogram (Bi) after the bipolar leads were im- 
planted. The R wave in the bipolar electrogram measures 15.7 mV. 
P-P 
Figure 3. Kecordings during defibrillation threshold testing at auto- 
matic implantable cardioverter-defibrillator (AICD) implantation. 
Shown are surface ECG leads I. II. III and aVR. the electrogram 
recorded from the two AICD patch electrodes (P-P) and the AICD 
bipolar rate sensing electrogram (Bi). A and B illustrate antitachy- 
cardia pacing during a nonclinical and rapid ventricular tachycardia 
(A) and ventricular fibrillation (B) in Patient 2 with a previously 
implanted Telectronics PASAR antitachycardia pacemaker. There 
is virtually no pacemaker stimulus artifact detectable in the bipolar 
rate-sensing electrogram (Bi) (asterisks) during pacing (arrows). B, 
The fourth through sixth impulses delivered during ventricular 
fibrillation are delivered from the antitachycardia pacemaker func- 
tioning in the ventricular demand mode. C, Similar recordings 
during defibrillation threshold testing are shown for Patient 8. who 
has a Telectronics (model 5282A) atrial demand pacemaker. Virtu- 
ally no pacemaker stimulus artifact is visible in the bipolar rate- 
sensing electrogram (Bi) (asterisks) during pacing (arrows). 
to recycle and rescue the patient with a second discharge 
when the first proved ineffective. 
In those patients vtith v~~ntriurlrrr tirc~hycurdia, arrhyth- 
mia conversion was also tested by either the AICD or the 
antitachycardia pacemaker (Fig. 7) as indicated. No inhibi- 
tion of AICD function by the pacemaker was observed. At 
postoperative electrophysiologic study, Patient 3 with an 
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Figure 4. A, An intraoperative automatic implantable cardioverter- 
defibrillator (AICD) defibrillation test for Patient 5, who has a 
combined Medtronic Activitrax II activity-sensing, rate-adaptive 
pacemaker and AICD system, when the pacemaker was programmed 
to its highest output (8 V) and pulse width (2 ms). Pacing occurred 
during this ventricular tachycardia, but the first AICD discharge 
successfully sensed and terminated the arrhythmia (sensing time of 
9.5 s, charging time of 7.2 s) without detection inhibition. Ventricular 
demand pacing followed the shock. B, With the AICD in the standby 
mode, ramp pacing induced ventricular fibrillation in Patient 2 who 
has a combined Telectronics PASAR antitachycardia pacemaker and 
AICD. After 17.0 s [standby time 4 s, sensing time (sense) 5.7 s, 
charging time (charge) 6.1 s and lag time after capacitor charging 1.2 
s], the AICD successfully terminated the arrhythmia. The antitachy- 
cardia pacemaker supported the cardiac rhythm after successful 
defibrillation but did not pace during the arrhythmia. C, Patient 2. 
Termination of ventricular tachycardia by an antitachycardia pace- 
maker is demonstrated. With the AICD in the standby mode and the 
antitachycardia pacemaker inactivated, programmed stimulation by 
way of the AICD bipolar leads (Bi) induced the patient’s clinical stable 
monomorphic ventricular tachycardia. Then both the antitachycardia 
pacemaker and the AICD were placed in their active modes. The first 
antitachycardia pacing burst (initial delay 380 ms, coupled delay 250 
ms) terminated the ventricular tachycardia and its first pacing se- 
quence. The AICD did not initiate a charging cycle because this 
tachycardia had a rate of only 115 beats/min and the AICD rate cutoff 
was 204 beats/min. Recordings are labeled as in previous figures. 
Intermedics Intertach pacemaker implanted for ventricular 
tachycardia was found to have had a change in his arrhyth- 
mia substrate. Whereas ventricular tachycardia had been 
easily inducible and hemodynamically well tolerated before 
AICD implantation, no ventricular tachycardia was induced 
postoperatively despite programmed stimulation with up to 
four extrastimuli. However, burst pacing induced ventricu- 
lar flutter. Although the antitachycardia pacemaker correctly 
recognized this arrhythmia as exceeding its detection rate 
and attempted to pace and terminate the arrhythmia, poly- 
morphic ventricular tachycardia was precipitated. Further- 
more, when the AICD discharged during a burst of pace- 
maker pulses, ventricular fibrillation was precipitated, 
thereby initiating a cycle of termination of ventricular fibril- 
lation by the AICD with reinitiation by the antitachycardia 
pacemaker. Similar arrhythmia acceleration by the devices 
in this patient had also been demonstrated intraoperatively 
(Fig. 8). Because the AICD can only deliver four pulses for 
one arrhythmia episode, an unsalvageable arrhythmia could 
have been precipitated. For this reason the patient was 
discharged from the hospital with the Intertach in the ven- 
tricular demand (VVI) mode. 
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Figure 5. Tracings recorded at postoperative elec- 
trophysiologic study in Patient 6. who has a Med- 
tronic Activitrax activity-sensing, rate-adaptive 
pacemaker. Surface ECG leads I, II, III and V, are 
shown with the right ventricular apex (RVA) electro- 
gram from a temporary electrode catheter advanced 
to the right ventricle for programmed stimulation. 
The automatic implantable cardioverter-defibrillator 
(AICD) was placed in the standby mode and ventric- 
ular fibrillation was induced. The AICD was then 
activated and despite ventricular demand pacing 
(arrows) during ventricular fibrillation, the AICD 
correctly identified and converted the arrhythmia. 
Note that the patient is pacemaker dependent after 
AICD discharge. 
Follow-up. The two patients with a PASAR antitachycar- 
dia device have reported self-terminating episodes of palpi- 
tation that are presumably due to ventricular tachycardia 
successfully treated by antitachycardia pacing. Patient 2 has 
also had AICD discharges. Immediately before one defibril- 
lation, transtelephonic monitoring documented ventricular 
tachycardia that was not terminated by the antitachycardia 
pacemaker. Patient 3 has had I I AICD discharges, the first 
one occurring 2 months after implantation. Syncope and 
ventricular tachycardia were documented. Patient 4 has 
been followed up for 3 months after implantation without 
any reported clinical event. However, interrogation of his 
intertach pacemaker revealed that a tachycardia with a cycle 
length of 492 ms had been detected and terminated on 3 
occasions. The sensed events were unlikely to have been 
sinus tachycardia because the maximal heart rate achieved 
during treadmill exercise testing was 83 beatsimin. The two 
patients (Patients 5 and 6) with an activity-sensing, rate- 
adaptive pacemaker remain well 10 and I I months, respec- 
tively. after implantation. Patient 6 with idiopathic dilated 
cardiomyopathy has used her AICD since pacemaker im- 
plantation. Patient 7 with a ventricular demand pacemaker 
experienced I7 appropriate discharges before he died later 
from pulmonary embolism. Patient 8 has also received an 
appropriate AICD discharge preceded by premonitory diz- 
ziness. Thus. five of the eight study patients have used their 
AICD successfully in the presence of their pacemaker. 
Figure 6. Recordings from the postoperative electrophysiologic 
study in Patient 8 with an automatic implantable cardioverter- 
defibrillator (AICD) and a Telectronics (model 5282A) atrial demand 
pacemaker. Channels I to 4 show surface ECG leads 1, II, III and 
V,. RA and RVA are endocardial electrograms recorded from a 
temporary electrode catheter from which the two proximal poles 
record the intracavitary right atrial (RA) electrogram and the distal 
poles record the right ventricular apical (RVA) electrogram. Ven- 
tricular fibrillation was induced by rapid ventricular pacing with the 
AICD in the standby mode. At the asterisk. the AICD was placed in 
the active mode. In the lower panel. the first AICD shock was 
delivered but ventricular fibrillation persisted. A second rescue 
shock terminated the arrhythmia. In the right atrial electrogram 
continued atrial demand pacing is shown during ventricular fibrilla- 
tion. The AICD recognition of ventricular fibrillation was not 
atfected. Recordings labeled as in previous figures. 
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Figure 7. Surface electrocardiographic leads and electrogram from a 
catheter inserted percutaneously at the right ventricular apex (RVA) 
in Patient I with a Telectronics PASAR antitachycardia pacemaker 
and an automatic implantable cardioverter-defibrillator (AICD) un- 
dergoing postoperative electrophysiologic study. Triple extrastimuli 
delivered during sinus rhythm (S&S,) induced the patient’s clinical 
right bundle/right superior axis ventricular tachycardia (rate 150 
beatsimin). The AICD was in the active mode during programmed 
stimulation, and 5 beats after the antitachycardia pacemaker was 
activated (asterisk) 7 pulses (S) were delivered and successfully 
restored sinus rhythm. Recordings labeled as in previous figures. 
Discussion 
Combined automatic implantable cardioverter-defibril- 
lator (AICD) and pacemaker implantation provides a sub- 
strate for potential adverse interactions between the two 
devices (2,13-23). Although successful implantation of com- 
bined AICD and pacemaker systems has been reported 
(2,7,25,26), we are not aware of a detailed description of the 
operative techniques. This report extends prior observations 
by describing an operative approach to combined AICD and 
pacemaker implantation. In the present study, no adverse 
device interactions occurred that could not be remedied by 
reprogramming the ventricular pacemaker. 
Order of AICD and pacemaker implantation. Our map- 
ping techniques allow localization of sites in the right ven- 
tricle for pacemaker lead implantation in patients with a 
previously implanted AICD pulse generator. Conversely, we 
have also successfully implanted an AICD pulse generator in 
patients with a previously implanted pacemaker. However, 
the pacemaker should be implanted first, if possible, for two 
reasons: 1) Regardless of which device is implanted first, the 
pacemaker lead and the AICD sensing lead or leads must be 
positioned so that the pacemaker stimulus artifact is small 
and not sensed by the AICD. It is potentially more difficult to 
identify a satisfactory right ventricular site for pacemaker 
lead implantation in a patient who already has an AICD 
implanted than it is to identify a satisfactory left ventricular 
site for AICD sensing lead implantation in a patient who 
already has a pacemaker. For a patient with an AICD that 
uses either a transvenous rate-counting electrode or an 
epicardial rate-counting lead system implanted near the right 
ventricle, locating a satisfactory right ventricular pacing site 
Figure 8. Intraoperative recordings 
from Patient 3, who has combined In- 
termedics Intertach antitachycardia 
pacemaker and automatic implantable 
cardioverter-defibrillator (AICD) sys- 
tem. A stable ventricular tachycardia 
was induced (first three beats of A) but 
antitachycardia pacing (arrows) pre- 
cipitated polymorphic ventricular 
tachycardia. This tachycardia regular- 
ized to become ventricular flutter (B). 
An AICD discharge (asterisk) during 
antitachycardia pacing (arrows) then 
precipitated ventricular fibrillation. A 
subsequent AICD discharge converted 
the arrhythmia but the hazard of a 
self-perpetuating tachycardia is docu- 
mented. Recordings labeled as in pre- 
vious figures. 
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may be impossible. necessitating a thoracotomy or sternot- 
omy for pacemaker lead implantation. 2) When the pace- 
maker is implanted first in a separate procedure, stable 
fixation of the endocardial lead is possible before AICD 
implantation which requires manipulation of the heart. 
Implantation of the AICD rate-sensing and defihrillating 
electrodes. Most adverse interactions can be avoided by 
implanting the AICD rate-sensing electrodes at a location 
that minimizes the amplitude of the pacemaker artifact. The 
external cardioverter-defibrillator is used to record the elec- 
trograms because its filtering system closely resembles that 
in the AICD. and the implanting physician is able to observe 
the electrograms as viewed by the AICD monitoring circuit 
itself. (The external cardioverter-defibrillator does not have 
an automatic gain control as does the AICD.) Optimal AICD 
sensing electrode position is demonstrated in Figures 3, 3 
and 4 because the pacemaker stimulus artifact is virtually 
invisible in the clectrogram of the AICD bipolar sensing 
lead. Special attention must be given to assure not only that 
the crholtrtc amplitude of the pacing stimulus is minimal, but 
also that its r.c/rrti)~ amplitude to the R wave is minimal 
because relatively large pacing stimuli in relation to the R 
wave can cause inhibition of arrhythmia detection and 
double counting. Neither complication was observed with 
our technique\. 
Because there is always the possibility that a pacemaker 
may become necessary in a patient after AICD implantation. 
we have abandoned using the transvenous bipolar sensing 
electrode (model BTIO, Cardiac Pacemakers, Inc.) and now 
routinely implant the bipolar sensing electrodes epicardially 
high on the lateral left ventricle 0.5 to I in. (I .37 to 2.54 cm) 
below the atrioventricular groove. By doing so. the possibil- 
ity of finding a satisfactory right ventricular pacing site is 
maximized in the event that a permanent pacemaker is 
required after AlCD implantation. If the AlCD sensing lead 
or leads were to be implanted endocardially in the right 
ventricular or epicardially over the right ventricle. it would 
be particularly difficult to fmd a sat&factory site in the right 
ventricle where a permanent pacemaker could be implanted 
without causing double counting and adverse interaction 
with the AICD. 
Importance of bipolar pacing. Unipolar pacing contra 
indicates AICD implantation (13-16.21,23). Figure 2B dcm- 
onstrates the difference between unipolar and bipolar pacing 
as recorded at a single AICD bipolar recording site. Al- 
though the vector orientations of the unipolar and bipolar 
paced signals were different in relation to the AICD rate- 
sensing electrodes. the amplitudes of the pacemaker stimu- 
lus artifacts were consistently larger during unipolar than 
during bipolar pacing. Nevertheless, even bipolar stimulus 
artifacts can be large (Fig. 2A) and if they are similar in 
amplitude to the amplitude of the R wave during ventricular 
tachycardia oi- ventricular fibrillation. then it may be neces- 
sary to move the bipolar sensing electrodes to avoid detec- 
tion inhibition by the pacemaker. 
Despite concerns about double counting and detection 
inhibition. we found implantation of the AICD rate-sensing 
electrodes quite simple in our patient with a bipolar atrial 
demand pacemaker, probably because the atrial pacing site 
was far removed from the ventricle. 
Risk of arrhythmia acceleration and importance of postop- 
erative electrophysiologic study. Several precautionary mea- 
sures can protect the patient against the repetitive reinitia- 
tion of hemodynamically unstable ventricular tachycardia or 
fibrillation by antitachycardia pacing as was observed in 
Patient 3 (Fig. 8). First, the slowest and shortest effective 
antitachycardia pacing bursts should be employed because 
faster and longer bursts may increase the likelihood of both 
tachycardia acceleration and AICD activation due to pacing. 
Second, because the AICD can deliver only four shocks for 
one sensed arrhythmia, consideration may be given to de- 
livery of two or at most three antitachycardia pacing bursts 
so that at least one or two AICD shocks are available for 
delivery in the absence of antitachycardia pacing. 
Pacemaker function and follow-up. Satisfactory pacing 
occurred in our patients after AICD discharge (Fig. 4 to 6). 
Although there have been reports of in,iury to implanted 
pacemakers by AICD shocks (17.18). this was not observed 
in our experience. 
BrcYlrrsc rr.\~n(,/I~orlolls \YJ,!tr.ic,/rlrr,. c VOO) pfK;ng mcr!, 
iuitirrtc \.cntricc//trr trrch~crrrtlin, and. in fact. did so in one of 
our patients, we arc now reluctant to allow patients with 
easily inducible ventricular tachycardia to have pacemaker 
checks at home. Asynchronous ventricular pacing can also 
result in AICD discharges when asynchronous pacemaker 
stimulus artifact\ are counted in addition to the native 
underlying R waves (24). Certainly, if the AICD is deacti- 
vated during pacemaker checks as has been advocated by 
others (24). this should not be done at home. Finally, if 
magnet pacemaker checks are done at home. they should not 
be done by the patient but rather by another individual 
because magnet movement across the abdomen may initiate 
an AICD charging cycle. 
Device limitations and future directions. In view of the 
various AICD-pacemaker interactions discussed and be- 
cause the current AICD is not programmable, the choice of 
the appropriate pacemaker to implant with an AICD and its 
programming are complex. Antitachycardia pacemakers are 
rapidly becoming more sophisticated, having greater versa- 
tility in both tachycardia detection and pacing. New gener- 
ation AlCDs will similarly have greater versatility in provid- 
ing the capability of not only programmability but also 
antitachycardia and ventricular demand pacing. Many of the 
problems that exist today will become obsolete when a 
combined AICD-antitachycardia pacemaker-ventricular de- 
mand pacemaker becomes available. These new devices 
should have a blanking period during pacing for the cardio- 
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verter-defibrillator sensing circuit to avoid double sensing 
and detection inhibition. Conversely, protection of the pace- 
maker circuitry during defibrillation is a necessity. Intrave- 
nous and subcutaneous lead systems are being developed 
such that cardioversion and defibrillation can be accom- 
plished without the need for epicardial patch placement. 
With these latter systems, both pacing and rate sensing can 
be accomplished by way of the transvenous lead itself. 
Finally, it is hoped that a combined device will have greater 
capability for high pacing output to overcome increased 
thresholds during periods of threshold rise, whether they 
occur acutely after implantation, during ischemia, during 
ventricular tachycardia or after a shock (1%20?22). 
Recommendations. 1) With the devices currently avail- 
able, only a bipolar pacemaker should be implanted in 
conjunction with an AICD. 
2) When an AICD is implanted alone, it should always be 
anticipated that antitachycardia or ventricular demand pac- 
ing may be needed in the future. For this reason, the bipolar 
rate-sensing electrodes should be placed epicardially and on 
the lateral left ventricle as far from the right ventricular apex 
as possible. We advise against implantation of AICD epicar- 
dial sensing electrodes over the right ventricle because 
future transvenous pacemaker electrode implantation in the 
right ventricle may be particularly difficult. 
3) When an AICD is implanted in a patient with a 
pacemaker, the left ventricle should always be mapped to 
find a site for AICD sensing lead implantation where the 
amplitude of the pacemaker stimulus is minimal even when 
the pacemaker is programmed to its highest output. 
4) Because locating such a site is possible only when the 
pacemaker is implanted before the AICD, pacemaker im- 
plantation should precede AICD implantation whenever 
possible. 
5) When combined AICD-pacemaker systems are im- 
planted, postoperative electrophysiologic study should al- 
ways be performed before patients are dismissed from the 
hospital to assure successful function of both devices and 
lack of adverse device interaction. Ventricular fibrillation 
should always be tested and ventricular tachycardia should 
also be tested when present. Electrophysiologic study is also 
important because arrhythmia substrates may change post- 
operatively. 
6) Whenever drug therapy is altered in patients with 
combined systems, repeat electrophysiologic study should 
be performed to assure satisfactory function of both devices 
(27-30). Antiarrhythmic drugs can alter pacing thresholds, 
defibrillation thresholds and tachycardia rates, rendering 
antitachycardia pacing more difficult and AICD recognition 
of the tachycardia perhaps impossible if the tachycardia rate 
declines below the rate cutoff of the AICD itself. 
The roles of pacing therapy and automatic cardioversion 
and defibrillation with the AICD are clearly established. The 
implantation of both a pacemaker and an AICD in one 
individual is significantly more complex than is that of either 
device alone. Nevertheless, with meticulous attention to 
detail and full understanding of potential interactions be- 
tween the devices, successful combined implantation can be 
performed. 
Addendum 
Since acceptance of this article, we have subsequently 
implanted an AICD in a patient with a Pacesetter model 
2010-T bipolar dual chamber (DDD) pacemaker demonstrat- 
ing the applicability of our techniques to not only single 
chamber but also dual chamber pacemakers implanted in 
conjunction with AICDs. 
We thank Lori Hagglund for diligence and care in preparing the manuscript. 
We also thank Cardiac Pacemakers, Inc. for providing photographic assis- 
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